Influence of Helicobacter pylori on the gastric mucosal barrier

Table 1 Potential difference in Helicobacter pylori positive or negative patients

Group	Antrum				Corpus
	n	Hp (+)	n	Hp (-)	n	Hp (+)	n	Hp (-)
CSG	5	17.96 ± 2.70	9	20.43 ± 2.08e	5	32.13 ± 3.79	9	32.93 ± 5.47
CAG	23	16.44 ± 2.36	20	19.58 ± 2.44e	25	31.74 ± 3.63	20	31.94 ± 4.84

^eP < 0.001, vs Hp (-). CSG: Chronic superficial gastritis; CAG: Chronic atrophic gastritis ; Hp: Helicobacter pylori.

Table 2 Potential difference in Helicobacter pylori (+) patients before and after treatment

Group	n	Antrum		Corpus		YPD
		before	after	before	after
I	9	16.88 ± 2.53	20.03 ± 2.21b	29.58 ± 2.50	32.41 ± 2.33	3.15 ± 1.9
II	6	16.50 ± 3.12	17.80 ± 3.63	31.84 ± 5.61	33.18 ± 4.22	1.30 ± 0.79
III	6	17.93 ± 2.58	17.53 ± 3.95	31.35 ± 1.57	31.33 ± 2.70	-0.39 ± 1.7

^bP < 0.01, YPD = elevated PD in antrum after treatment. Group I: The De-Nol treatment; Group II: The WeiTong-Ling treatment; Group III: Placebo; PD: Potential difference.

Table 3 Potential difference in Helicobacter pylori (-) patients before and after treatment

Group	n	Antrum		Corpus		YPD
		before	after	before	after
I	9	18.78 ± 2.50	20.11 ± 2.46	32.73 ± 3.61	33.30 ± 3.09	1.34 ± 2.37
II	9	19.69 ± 2.71	20.86 ± 1.99	34.27 ± 5.26	34.54 ± 4.97	1.17 ± 1.34
III	4	19.46 ± 2.99	19.67 ± 2.53	37.13 ± 3.32	36.96 ± 3.42	0.21 ± 0.39

Group I: The De-Nol treatment; Group II: The WeiTong-Ling treatment; Group III: Placebo; YPD: Elevated potential difference in antrum after treatment.